Ace inhibitors comparison
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors: Comparative Efficacy and Safety in Hypertension and Heart Failure
Blood Pressure Lowering and Cardiovascular Outcomes
ACE inhibitors and angiotensin receptor blockers (ARBs) are both widely used as first-line treatments for hypertension and heart failure. Multiple large-scale studies and systematic reviews have shown that ACE inhibitors and ARBs are equally effective in lowering blood pressure and reducing the risk of major cardiovascular events, such as heart attack, stroke, and heart failure, with no statistically significant differences in these primary outcomes 2345+1 MORE. Both drug classes are also effective in reducing the risk of kidney failure and cardiovascular events in patients with chronic kidney disease (CKD), though some evidence suggests ACE inhibitors may offer a slight advantage in reducing all-cause mortality in CKD patients .
Side Effects and Tolerability
The main difference between ACE inhibitors and ARBs lies in their side effect profiles. ACE inhibitors are more likely to cause bradykinin-mediated side effects, such as dry cough and angioedema, while ARBs have a lower risk of these adverse effects 2456. This improved tolerability with ARBs often leads to fewer withdrawals due to adverse effects compared to ACE inhibitors 56. For patients who experience cough or angioedema with ACE inhibitors, switching to an ARB is generally recommended.
Comparative Efficacy in Special Populations
In patients with CKD, both ACE inhibitors and ARBs reduce the risk of kidney failure and major cardiovascular events, but ACE inhibitors may be more effective in reducing all-cause mortality and possibly kidney failure and cardiovascular death . In terms of insulin sensitivity, ACE inhibitors may provide greater improvement than ARBs, especially in long-term use and among hypertensive patients with diabetes, although the overall differences are modest and more research is needed .
Differences Among ACE Inhibitors
Within the ACE inhibitor class, there are differences in pharmacokinetics, metabolism, and tissue distribution. For example, some ACE inhibitors like lisinopril and captopril do not require hepatic activation, making them suitable for patients with liver disease, while others like fosinopril have dual routes of elimination and may be preferred in patients with renal impairment 1910. The duration and magnitude of ACE inhibition can also vary, with drugs like ramipril, lisinopril, and zofenopril showing longer-lasting effects in some tissues . However, these differences are generally not clinically significant when optimal dosing is used, except in special populations or specific clinical scenarios 910.
Clinical Implications
Current guidelines recommend both ACE inhibitors and ARBs as first-line options for hypertension and heart failure, with the choice often guided by individual patient tolerability and comorbidities 2345+1 MORE. ARBs may be preferred for patients who develop cough or angioedema on ACE inhibitors, while ACE inhibitors may be favored in CKD patients for potential mortality benefits . Within the ACE inhibitor class, drug selection can be tailored based on patient-specific factors such as liver or kidney function .
Conclusion
ACE inhibitors and ARBs are equally effective for most patients in managing hypertension and heart failure, with ARBs offering better tolerability due to fewer side effects like cough and angioedema. ACE inhibitors may have a slight advantage in certain populations, such as those with CKD or diabetes, but the differences are generally small. The choice between these agents should be individualized, considering patient comorbidities, risk of side effects, and specific pharmacokinetic properties of each drug.
Sources and full results
Most relevant research papers on this topic